Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

parathyroid hormone

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

Shire extends rare genetic disease alliance

Agrees option with Santaris to nominate additional discovery targets

- PMLiVE

Novartis orphan drug wins ‘breakthrough’ status from FDA

Bimagrumab could be first treatment for rare life-threatening muscle-wasting condition

Shire hires adviser on takeover threat

Reports suggest it could be the latest Irish pharma company to be acquired

Novartis building

Novartis drawn into Chinese corruption probe

Former sales rep files bribery complaint about Sandostatin LAR prescribing practices

- PMLiVE

Outcomes shape the new European payer networks

In the new commercial reality of cost-constrained healthcare environments the payer is everywhere

EU flag

Europe backs two blood cancer treatments

Approvals for J&J’s Velcade and Celgene’s Imnovid for treatment of multiple myeloma

Novartis building

Novartis says Afinitor fails liver cancer trial

Halts plans to file for approval in new indication

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

Novartis building

Novartis lifts 2013 guidance on delay to Diovan generics

Reveals scale of payments to former CEO Daniel Vasella

- PMLiVE

J&J gets pharma Q2 results off to a flying start

OTC recovery and Synthes acquisition help boost sales performance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links